Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
May 11, 2023 07:30 ET
|
Century Therapeutics, Inc.
– Preclinical data supporting selection of CNTY-101 as lead product candidate presented at AACR Annual Meeting – – Company remains on track to report initial data from Schedule A of the ongoing...
Century Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit
April 17, 2023 07:00 ET
|
Century Therapeutics, Inc.
PHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell...
Century Therapeutics Announces Leadership Changes
April 12, 2023 08:30 ET
|
Century Therapeutics, Inc.
– Lalo Flores, Ph.D., steps down as Chief Executive Officer and member of Board of Directors; Greg Russotti, Ph.D., Chief Technology Officer, assumes role of ad-interim Chief Executive Officer – –...
Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates
March 16, 2023 07:30 ET
|
Century Therapeutics, Inc.
- Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory CD19 positive B-cell lymphomas underway - - Ended 2022 with cash, cash equivalents, and investments of $367.4 million; Cash runway expected...
Century Therapeutics to Present at the AACR Annual Meeting 2023
March 15, 2023 16:01 ET
|
Century Therapeutics, Inc.
PHILADELPHIA, March 15, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell...
Century Therapeutics to Present at Upcoming Investor Conferences
February 21, 2023 07:00 ET
|
Century Therapeutics, Inc.
PHILADELPHIA, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell...
Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas
February 08, 2023 07:30 ET
|
Century Therapeutics, Inc.
– CNTY-101 is the first cell therapy product candidate engineered with six precision gene edits including a CD19-CAR, Allo-Evasion™ technology, IL-15 cytokine support and a safety switch – –...
Century Therapeutics to Present at Upcoming Investor Conferences
February 01, 2023 07:00 ET
|
Century Therapeutics, Inc.
PHILADELPHIA, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...
Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026
January 05, 2023 16:01 ET
|
Century Therapeutics, Inc.
- Prioritization allows for acceleration of key programs including CNTY-107 in Nectin-4+ tumors, while de-prioritizing further investment in CNTY-103 for glioblastoma - - Employee headcount reduced...
Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 04, 2023 07:00 ET
|
Century Therapeutics, Inc.
PHILADELPHIA, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in...